Publications: Our research

Filter
Research Area
Technology
Resource type
Category
135 results found
Jan 24, 2024
Publication
Novavax led
Vaccine
COVID-19, Matrix-M™ adjuvant
Burden and Impact of Reactogenicity among Adults Receiving COVID-19 Vaccines in the United States and Canada: Results from a Prospective Observational Study
Matthew Rousculp, Kelly Hollis, Ryan Ziemiecki, et al.
Jan 18, 2024
Publication
Novavax led
Preprint
COVID-19, Matrix-M™ adjuvant
Altered IgG4 Antibody Response to Repeated mRNA versus Protein COVID Vaccines
Raj Kalkeri, Mingzhu Zhu, Shane Cloney-Clark, et al.
Nov 22, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M™ adjuvant
The Novavax Heterologous COVID Booster Demonstrates Lower Reactogenicity Than mRNA: A Targeted Review
Anthony M. Marchese, Matthew Rousculp, John Macbeth, et al.
Nov 16, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-cov-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial
Chijioke Bennett, E Joy Rivers, Wayne Woo, et al.
Nov 7, 2023
Publication
Novavax led
Frontiers in Drug Delivery
COVID-19, Matrix-M™ adjuvant
Biodistribution of the Saponin-Based Adjuvant Matrix-M™ Following Intramuscular Injection in Mice
Cecilia Carnrot, Berit Carow, Anna-Karin E. Palm, et al.
Nov 6, 2023
Publication
Novavax led
Scientific Reports
COVID-19, Matrix-M™ adjuvant
XBB.1.5 spike protein COVID‑19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
Nita Patel, Jessica F. Trost, Mimi Guebre‑Xabier, et al.
Sep 20, 2023
Publication
Novavax led
Vaccine
COVID-19
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
Bethanie Wilkinson, Kinjal S. Patel, Katherine Smith, et al.
Sep 20, 2023
Publication
Novavax included/third party
eBioMedicine
COVID-19, Matrix-M™ adjuvant
Risk of COVID-19 after natural infection or vaccination
Anne-Marie Rick, Matthew B. Laurens, Ying Huang, et al.
Aug 31, 2023
Publication
Novavax led
Preprint
COVID-19, Matrix-M™ adjuvant
XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants
Aug 30, 2023
Publication
Collaborative
Vaccine
COVID-19, Matrix-M™ adjuvant
Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults